Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML.

Cook, Jacqueline A; Lott, Loren; Perry, Jenna; Eckel, Ashley M; Xu, Dongbin; Hudson, Chad A; Wells, Denise A; Loken, Michael R; Menssen, Andrew J

Cook, Jacqueline A; Lott, Loren; Perry, Jenna; Eckel, Ashley M; Xu, Dongbin; Hudson, Chad A; Wells, Denise A; Loken, Michael R; Menssen, Andrew J.

Afiliación

Cook JA; Hematologics, Inc., Seattle, Washington, United States.
Lott L; Hematologics, Inc., Seattle, Washington, United States.
Perry J; Hematologics, Inc., Seattle, Washington, United States.
Eckel AM; Hematologics, Inc., Seattle, Washington, United States.
Xu D; Hematologics, Inc., Seattle, Washington, United States.
Hudson CA; Hematologics, Inc., Seattle, Washington, United States.
Wells DA; Hematologics, Inc., Seattle, Washington, United States.
Loken MR; HematoLogics Inc, Seattle, Washington, United States.
Menssen AJ; Hematologics, Inc., Seattle, Washington, United States.

Blood ; 2024 May 15.

Article en En | MEDLINE | ID: mdl-38749014

ABSTRACT

ABSTRACT

Molecular measurable residual disease (MRD) can persist in core binding factor acute myeloid leukemia (AML) in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google